The company is substantially advanced the development of a new treatment for cardiac amyloidosis, leveraging the investigational drug. Early patient results reveals potential outcomes for patients diagnosed from this https://bridgebio017391.blogozz.com/40888290/bridgebio-improves-attr-cm-therapy-through-the-drug